<DOC>
	<DOCNO>NCT01321034</DOCNO>
	<brief_summary>Objectives . - To evaluate absolute relative Lp ( ) lower effect 1g/20 mg 2 g/40 mg day Niacin/Laropiprant subject normal Lp ( ) ( &lt; 30 mg/dL ) , high Lp ( ) ( 30-60 mg/dL ) high Lp ( ) ( &gt; 60 mg/dL ) . - To evaluate absolute relative Lp ( ) lower effect 1g/20 mg 2 g/40 mg day Niacin/Laropiprant depend number kringle IV-2 repeated copy apo ( ) gene . 2.1.1 Hypotheses . - The Lp ( ) lower effect niacin dependent pre-treatment Lp ( ) concentration , high absolute relative reduction Lp ( ) subject hyperlipoproteinemia ( ) . - Lp ( ) size , throughout modify hepatic synthesis apo ( ) , major factor relate lower effect variability niacin human .</brief_summary>
	<brief_title>Effect Niacin Lipoprotein ( ) Concentration</brief_title>
	<detailed_description>Open-label 12-week study , 1g/20 mg day Niacin/Laropiprant 4-weeks follow 8 additional week 2 g/40 mg day . Subjects normal Lp ( ) use comparative group two group , placebo group require study . Subjects : volunteer Lipid Clinic Hospital Universitario Miguel Servet Zaragoza , Spain . Subjects select accord previously determine Lp ( ) concentration . All volunteer study procedure give write inform consent protocol previously approve Ethical Committees institution . Biochemical determination : lipid : total cholesterol triglyceride ; lipoprotein : HDL-cholesterol , Lp ( ) ; apolipoproteins : Apo A1 apo B safety biochemical parameter ( glucose , uric acid , creatinine , liver muscle enzyme measure baseline end two treatment period ( week 4 8 ) . An adverse experience questionnaire do visit . Genetic analysis : apo ( ) genetic polymorphism responsible Lp ( ) size variability analyze PCR-based methodology ( Lanktree et al . J Lipid Res 2009 ; 50 : 768-72 ) .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>1 . Age &gt; 18 &lt; 80 year 2 . LDL cholesterol 70 190 mg/dL 3 . Triglycerides &lt; 500 mg/dL 4 . At least 2 Lp ( ) determination previous begin study without difference &gt; 20 % &gt; 20 mg/dL . 5 . No lipid lower therapy stable dos last 3 month 1 . Liver disease liver enzymes &gt; 2 time high reference value 2 . Creatinine &gt; 2 mg/dL 3 . Active peptic ulcer 4 . Clinical gout last year 5 . Uncontrolled diabetes ( HbA1c &gt; 8 % ) 6 . Enrolment drug clinical trial previous 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Lipoprotein ( )</keyword>
	<keyword>LPA</keyword>
	<keyword>Niacin</keyword>
	<keyword>Kringle IV-2 repeat</keyword>
</DOC>